The effect of raleukin on the values of glucose homeostasis of normoglycemic rats in glucose load

Abstract

Intraperitoneal and oral glucose tolerance test; hypoglycemic effect; raleukin Diabetes mellitus (DM) remains the only noncontagious disease for today, which prevalence, according to the World Health Organization, has reached epidemic proportions. According to the results of recent research proinflammatory cytokines, namely interleukin-1 (IL-1), play an important role in the pathogenesis of both types of diabetes. Therefore, drugs that can inhibit the activity of IL-1 by suppressing its receptors, improve survival and normalize the functional activity of β-cells of the pancreas are promising anti-diabetic agents. The article presents the results of the pharmacological screening of hypoglycemic properties of receptor antagonist IL-1 raleukin obtained in the Research Institute of High-Purity Biopharmaceuticals (St. Petersburg) in normoglycemic rats under conditions of tolerance tests to carbohydrates. It has been found that in the intraperitoneal glucose tolerance test the antagonist of IL-1 raleukin shows a significant hypoglycemic effect in the doses of 7 and 10 mg/kg, i.e. it is a promising antidiabetic agent. In the oral glucose tolerance test raleukin in the dose of 7 mg/kg revealed the same hypoglycemic activity. This dose is a conditionally effective dose of the drug by the hypoglycemic effect; it can be used in further studies of anti-diabetic properties of raleukin. The results experimentally substantiate the high efficiency and expediency of IL-1 receptors blockade as one of the ways of correcting hyperglycemia in type 1 diabetes.